|
1
|
Bosse KR and Maris JM: Advances in the
translational genomics of neuroblastoma: From improving risk
stratification and revealing novel biology to identifying
actionable genomic alterations. Cancer. 122:20–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He J, Wang F, Zhu J, Zhang R, Yang T, Zou
Y and Xia H: Association of potentially functional variants in the
XPG gene with neuroblastoma risk in a Chinese population. J Cell
Mol Med. 20:1481–1490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ham J, Costa C, Sano R, Lochmann TL,
Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata
AN, et al: Exploitation of the apoptosis-primed state of
MYCN-amplified neuroblastoma to develop a potent and specific
targeted therapy combination. Cancer Cell. 29:159–172. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Speleman F, Park JR and Henderson TO:
Neuroblastoma: A tough nut to crack. Am Soc Clin Oncol Educ Book.
35:e548–e557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shipley MM, Mangold CA and Szpara ML:
Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis
Exp. 108:531932016.
|
|
6
|
Wilczynska A and Bushell M: The complexity
of miRNA- mediated repression. Cell Death Differ. 22:22–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang
B, Kou Z, Guo Z, He S, Xue X, et al: Upregulated expression of
miR-106a by DNA hypomethylation plays an oncogenic role in
hepatocellular carcinoma. Tumour Biol. 36:3093–3100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ:
miR-106b promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. World J Gastroenterol.
22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thind A and Wilson C: Exosomal miRNAs as
cancer biomarkers and therapeutic targets. J Extracell Vesicles.
5:312922016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gholamin S, Mirzaei H, Razavi SM,
Hassanian SM, Saadatpour L, Masoudifar A, Shahid Sales S and Avan
A: GD2-targeted immunotherapy and potential value of circulating
microRNAs in neuroblastoma. J Cell Physiol. 233:866–879. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maugeri M, Barbagallo D, Barbagallo C,
Banelli B, Di Mauro S, Purrello F, Magro G, Ragusa M, Di Pietro C,
Romani M, et al: Altered expression of miRNAs and methylation of
their promoters are correlated in neuroblastoma. Oncotarget.
7:83330–83341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nalavenkata SB, Sacks R, Adappa ND, Palmer
JN, Purkey MT, Feldman MD, Schlosser RJ, Snyderman CH, Wang EW,
Woodworth BA, et al: Olfactory neuroblastoma: Fate of the neck - a
long-term multicenter retrospective study. Otolaryngol Head Neck
Surg. 154:383–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao Y, Eissler N, Blanc KL, Johnsen JI,
Kogner P and Kiessling R: Targeting suppressive myeloid cells
potentiates checkpoint inhibitors to control spontaneous
neuroblastoma. Clin Cancer Res. 22:3849–3859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ho WL, Hsu WM, Huang MC, Kadomatsu K and
Nakagawara A: Protein glycosylation in cancers and its potential
therapeutic applications in neuroblastoma. J Hematol Oncol.
9:1002016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohammadi M, Goodarzi M, Jaafari MR,
Mirzaei HR and Mirzaei H: Circulating microRNA: A new candidate for
diagnostic biomarker in neuroblastoma. Cancer Gene Ther.
23:371–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Png KJ, Halberg N, Yoshida M and Tavazoie
SF: A microRNA regulon that mediates endothelial recruitment and
metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo J, Dong Q, Fang Z, Chen X, Lu H, Wang
K, Yin Y, Cai X, Zhao N, Chen J, et al: Identification of miRNAs
that are associated with tumor metastasis in neuroblastoma. Cancer
Biol Ther. 9:446–452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Aurora AB, Johnson BA, Qi X,
McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Madhavan D, Peng C, Wallwiener M, Zucknick
M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, et
al: Circulating miRNAs with prognostic value in metastatic breast
cancer and for early detection of metastasis. Carcinogenesis.
37:461–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wang H, Li J and Yue W: MiR-181c
modulates the proliferation, migration, and invasion of
neuroblastoma cells by targeting Smad7. Acta Biochim Biophys Sin
(Shanghai). 46:48–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Das S, Bedja D, Campbell N, Dunkerly B,
Chenna V, Maitra A and Steenbergen C: miR-181c regulates the
mitochondrial genome, bioenergetics, and propensity for heart
failure in vivo. PLoS One. 9:e968202014. View Article : Google Scholar : PubMed/NCBI
|
